GlassScriptPhysician profile
Lisa B Laya
NPI 1427046622
$4,424.52
in general payments reported to CMS, 2019-2025
21 companies · $896 in 2025
The $896 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $526 · 2021: $426 · 2022: $556 · 2023: $568 · 2024: $294 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $73.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.86 |
| Education | $73.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $798.85 | 2019-2025 | Biktarvy |
| Insmed, INC. | $596.69 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $571.33 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Products, LP | $547.21 | 2019-2022 | |
| Viiv Healthcare Company | $337.11 | 2022-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $326.25 | 2019-2025 | |
| La Jolla Pharmaceutical Company | $233.24 | 2022-2025 | Xacduro, Xerava, Zevtera |
| Melinta Therapeutics, LLC | $192.30 | 2019-2025 | Rezzayo |
| Janssen Biotech, INC. | $179.44 | 2019-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $145.59 | 2025 | Vibativ, Caldolor |
| Paratek Pharmaceuticals, INC. | $123.20 | 2020-2025 | Nuzyra |
| Ferring Pharmaceuticals INC. | $72.00 | 2022-2023 | Rebyota |
| Allergan, INC. | $58.24 | 2019-2020 | |
| Emd Serono, INC. | $51.64 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $47.12 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $40.85 | 2022 | |
| Astellas Pharma US INC | $29.80 | 2019 | |
| Mayne Pharma Commercial LLC | $26.72 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.15 | 2020 | |
| Pfizer INC. | $14.91 | 2024 | |
| Theratechnologies INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Laya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.